New Delhi, Feb 7 (IANS) Hyderabad-based pharmaceutical firm Dr. Reddy's Laboratories Monday said it has initiated clinical trials for its cardiovascular drug in Ireland.
"The phase-one clinical trails are being conducted in Belfast and will explore the safety and pharmacokinetic profiles of drug candidate RUS 3108 in humans. This is the first time the company is testing a drug in Europe," the company said in a statement to the Bombay Stock Exchange Monday.
RUS 3108 is being developed for the treatment of atherosclerosis, a major cause of cardiovascular disorders such as heart attacks and strokes. There are currently no drugs in the market that can directly treat atherosclerosis.
"RUS 3018 represents a unique treatment approach to the cardiovascular disease," said Uday Saxena, CEO of Dr. Reddy's Laboratories, in the statement
The drug candidate works through multiple pathways involved in the disease such as inflammation, proliferation and thrombosis by inducing a protein called perlecan.
Company scientists have determined that regulating the expression of perlecan can provide direct protection against atherosclerosis.
New Delhi, November 18 -- Since its outbreak in June this year, the H1N1 influenza has taken a widespread toll. With four more H1N1 deaths in India, the toll goes up to 530, as per an official statement.
We seeks happiness even as it continues to elude many of us. However, the fact is that if we focus our attention on other things and not strive for happiness itself, we will experience this emotion more often.
You have just met your Mr. Right and with all your womanly intuition you feel that he is the one you have been waiting for. You are excited, can`t stop smiling and your cheeks turn red the moment he enters.
Disclaimer: The views and ideas expressed by medical experts on themedguru.com are their own, and not that of the website or its management. TheMedGuru advises users to check with their certified experts for their healthcare needs.
The comments and views posted by readers are their own and not that of the website or its management. Please see our 'Terms of Service' for details.
Post new comment